The recurrence-free survival (RFS), from the diagnosis of primary melanoma tumor (stage I/II) to the development of distant metastases (stage IV), does not significantly differ between BRAF(+) and BRAF WT patients, but at the same time, the median OS of patients with newly diagnosed, untreated, metastatic BRAF(+) melanoma was historically 5.7 months, and for BRAF WT patients, 8.5 months [18]. The gene discussed is BRAF; the disease is melanoma.